Equality of Access to Health Care for Ethnic Minorities: Diabetes Control in South Asians and White Patients with Non-Insulin Dependent Diabetes Mellitus

1993 ◽  
Vol 84 (s28) ◽  
pp. 42P-42P
Author(s):  
M Roshan ◽  
C Sherriff ◽  
ML Burden ◽  
SE Butterworth ◽  
H Kinghorn ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Health Care ◽  
Ethnic Minorities ◽  
Access To Health Care ◽  
South Asians ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Access To Health ◽  
Insulin Dependent

scholarly journals Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus.

1992 ◽  
Vol 3 (4) ◽  
pp. S111
Author(s):  
J E Siegel ◽  
A S Krolewski ◽  
J H Warram ◽  
M C Weinstein
Keyword(s):  
Diabetes Mellitus ◽  
Health Care ◽  
Cost Effectiveness ◽  
Early Treatment ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Future Research ◽  
Improve Life Expectancy ◽  
Insulin Dependent

Studies have demonstrated that "antihypertensive" treatment with angiotensin-converting enzyme inhibitors (ACEI) may retard the progress of nephropathy in patients with insulin-dependent diabetes mellitus. To obtain an indication of the potential effect of ACEI treatment and as a guide to future research, the effects of screening and early ACEI treatment programs were estimated using cost-effectiveness models. The preliminary analysis suggests that the early treatment of insulin-dependent diabetes mellitus patients with ACEI is likely to be a very cost-effective use of health care resources. The cost-effectiveness ratio for screening and treatment at the stage of microalbuminuria ($7,900 to $16,500 per year of life saved) compares favorably with those of other medical life-saving interventions. Less-aggressive programs (screening followed by treatment at the stage of proteinuria) would improve life expectancy to a lesser extent but could save net health care costs as well as years of life. Although more exact and comprehensive cost-effectiveness analysis must await clinical trials, these illustrative results demonstrate the range of cost-effectiveness that can be expected from these programs and identify data needed for more decisive policy conclusions.

Sign in / Sign up

Export Citation Format

Share Document